Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that it has entered into a definitive arrangement agreement (the “Arrangement Agreement“) pursuant to which Aditxt Inc. (NASDAQ: ADTX) (“Aditxt”), a Richmond, Virginia- based company dedicated to discovering, developing, and deploying promising… Continue reading Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

Sexually transmitted infections (STIs) are on the rise among older adults, with rates of chlamydia, gonorrhea, and syphilis more than doubling in people aged 55 and up over the decade from 2012 to 2022, according to data from the Centers for Disease Control and Prevention. This increase is alarming, highlighting a growing health concern that… Continue reading Sexually transmitted infection rates have risen sharply among adults 55 and older, CDC data shows

Walgreens reported fiscal second-quarter sales that surpassed expectations but adjusted its full-year earnings outlook downwards, citing challenges in the U.S. retail environment. The company incurred a significant net loss due to a substantial charge related to the decline in value of its investment in primary-care provider VillageMD. Despite this, Walgreens remains committed to its transformation… Continue reading Walgreens tops quarterly revenue estimates, but narrows profit outlook in ‘challenging’ economy

Altimmune’s experimental drug has shown promising results in a midstage trial, demonstrating its potential to address concerns surrounding weight loss treatments by minimizing the loss of muscle mass while aiding in shedding weight. The trial revealed that over 74% of weight lost by patients who received Altimmune’s weekly injection was from fat tissue, with only… Continue reading Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart

TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has submitted a Type C meeting request package to the U.S. Food &… Continue reading Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

Amgen is taking a pioneering approach in the competitive realm of weight loss drug development with its experimental treatment, MariTide, which offers a distinct mechanism from existing medications like Wegovy and Zepbound. MariTide, administered through monthly injections, not only aids in weight loss by activating gut hormone receptor GLP-1 but also uniquely blocks GIP, offering… Continue reading Amgen wants in on the booming weight loss drug market — and it’s taking a different approach

Nvidia made significant strides in the healthcare sector during its 2024 GTC AI conference, unveiling partnerships with Johnson & Johnson and GE Healthcare, alongside the launch of numerous AI-powered healthcare tools. These developments underscore Nvidia’s growing interest in healthcare, a sector with immense revenue potential beyond its traditional tech focus. With Nvidia shares up nearly… Continue reading Nvidia’s AI ambitions in medicine and health care are becoming clear

A recent study published in The Lancet medical journal reveals that falling fertility rates are poised to trigger a significant demographic transformation over the next quarter-century, with far-reaching implications for the global economy. By 2050, an estimated three-quarters of countries are projected to fall below the population replacement birth rate of 2.1 babies per female,… Continue reading Falling fertility rates pose major challenges for the global economy, report finds

Neuralink, Elon Musk’s brain-computer interface (BCI) startup, showcased a live video demonstrating its brain implant technology, featuring Noland Arbaugh as the first human patient to receive the device. The implant, known as Telepathy, aims to enable individuals with severe paralysis to control external devices using neural signals. Arbaugh, a quadriplegic due to a diving accident,… Continue reading Neuralink shares video of patient playing chess using signals from brain implant

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it will present at the Emerging Growth Conference on April 3, 2024. The company invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging… Continue reading Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.

Johnson & Johnson (J&J) has announced a collaboration with Nvidia to develop and scale new artificial intelligence (AI) applications for surgery. The partnership between J&J’s MedTech unit and Nvidia aims to integrate AI within surgical devices and platforms, spanning from pre-op to post-op, to provide surgeons with comprehensive information during procedures. Nvidia’s vice president of… Continue reading Nvidia and Johnson & Johnson to develop new AI applications for surgery

The U.S. Food and Drug Administration (FDA) has issued a safety communication warning about Chinese-made plastic syringes distributed in the U.S., revealing more widespread quality control issues than previously acknowledged. Three Chinese syringe manufacturers were found to be in violation of FDA regulations, prompting the agency to send warning letters to them and two U.S.… Continue reading FDA says safety issues with China-made syringes are ‘more widespread’ than previously known